National Patterns of Filled Prescriptions and Third-Line Treatment Utilization for Privately Insured Women With Overactive Bladder
Authors:
- Brian J. LinderBLBrian J. Linder
- Holly K. Van HoutenHHHolly K. Van Houten
- Lindsey R. SangaralinghamLSLindsey R. Sangaralingham
- 1 February 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 27 (2) , e261-e266
Abstract
Objective: The aim of this study was to evaluate national patterns of care for women with overactive bladder (OAB) in an administrative data set and identify potential areas for improvement. Methods: We performed an analysis using the OptumLabs Data Warehouse, which contains deidentified administrative claims data from a large national US health insurance plan. The study included women, older than 18 years, with a new OAB diagnosis from January 1, 2007, to June 30, 2017. We excluded those with an underlying neurologic etiology, with interstitial cystitis/painful bladder syndrome, were pregnant, or did not have continuous enrollment for 12 months before and after OAB diagnosis. Trends in management were assessed via the Cochran-Armitage test. Time to discontinuation among medications was compared using t test. Results: Of 1.4 million women in the database during the study time frame, 60,246 (4%) were included in the study. Median age was 61 years [interquartile range (IQR), 50–73], and median follow-up was 2.6 years (IQR, 1.6–4.2). Overall, 37% were treated with anticholinergics, 5% with beta-3 agonists, 7% with topical estrogen, and 2% with pelvic floor physical therapy; 26% saw a specialist; and 2% underwent third-line therapy. Median time to cessation of prescription filling was longer for beta-3 agonists versus anticholinergics [median, 4.1 months (IQR, 1–15) vs 3.6 months (IQR, 1–10); P < 0.0001]. Use of third-line therapies significantly increased over the study time frame, from 1.1% to 2.2% ( P < 0.0001). Conclusions: Most of the patients do not continue filling prescriptions for OAB medications, and a minority of patients were referred for specialty evaluation. Although third-line therapy use is increasing, it is used in a small proportion of women with OAB. Given these patterns, there may be underutilization of specialist referral and other OAB therapies.Keywords
This publication has 12 references indexed in Scilit:
- Use of Third Line Therapy for Overactive Bladder in a Practice with Multiple Subspecialty Providers—Are We Doing Enough?Journal of Urology, 2018
- Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive BladderJournal of Urology, 2017
- Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical PracticeEuropean Urology, 2017
- Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older AdultsJAMA Neurology, 2016
- Real-World Patterns of Care for the Overactive Bladder Syndrome in the United StatesUrology, 2016
- Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline AmendmentJournal of Urology, 2015
- Optum Labs: Building A Novel Node In The Learning Health Care SystemHealth Affairs, 2014
- Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experienceBJU International, 2012
- Patient‐reported reasons for discontinuing overactive bladder medicationBJU International, 2010
- Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC StudyEuropean Urology, 2006